近端瘤颈解剖对新一代低 profile 内移植物治疗腹主动脉瘤短期和中期结局的影响:多中心 ITA-ENDOBOOT 登记研究结果
该多中心回顾性研究纳入137例接受 Bolton Treo 内移植物 EVAR 的腹主动脉瘤患者,其中63例(46%)为不良瘤颈(HAN),74例(54%)为良好瘤颈(FAN)。随访中位30个月,HAN组3年免于Ia型内漏率显著低于FAN组(87% vs 94%,P=0.02),但免于再干预率无显著差异。结论认为HAN与Ia型内漏相关,后者可能导致再干预。
要点
- 137例EVAR患者中46%为不良瘤颈(HAN),54%为良好瘤颈(FAN)。
- HAN组3年免于Ia型内漏率显著低于FAN组(87% vs 94%,P=0.02)。
- 两组3年免于再干预率无显著差异(80% vs 86%,P=0.28)。
核心结论
- 在当代多中心真实世界经验中,使用 Bolton Treo 内移植物行EVAR在术后早期安全性令人满意,中期随访结局可接受;HAN与Ia型内漏(早期或晚期)相关,后者可能是导致再干预的重要因素。
研究设计与样本
- 回顾性审查2016年1月至2020年12月在意大利东北部5家机构连续接受择期或非择期 Bolton Treo 内移植物EVAR的患者,主要暴露变量为不良瘤颈(HAN)或良好瘤颈(FAN)。
主要发现
- 共137例连续患者接受 Bolton Treo 内移植物治疗,其中63例(46%)为HAN,74例(54%)为FAN。
- 完成血管造影时检测到2例Ia型内漏,均在HAN组,FAN组无(3% vs 0%,P=0.04);全队列未发现III型内漏。
- 随访中位30个月(IQR 22-34个月),两组相似(P=0.87);3年生存率HAN组89% vs FAN组91%(P=0.82)。
- 3年时HAN组免于Ia型内漏率显著低于FAN组(87% vs 94%,P=0.02);两组3年免于再干预率无显著差异(80% vs 86%,P=0.28)。
- 单变量分析中,II型内漏(HR 3.15,95%CI 1.18-8.5,P=0.02)和Ia型内漏(HR 4.22,95%CI 1.39-12.85,P=0.01)为再干预的独立预测因素,但在多变量模型中不再显著;3年免于瘤囊增大>5mm两组无显著差异(92% vs 91%,P=0.95)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of the study was to evaluate the short-term and mid-term technical and clinical outcomes of the Bolton Treo endograft in subjects with abdominal aortic aneurysm (AAA) requiring endovascular aortic repair (EVAR) and assess if presence of hostile proximal neck would represent a risk factor for increased failure rates. METHODS: A retrospective review of all consecutive patients who had undergone elective or non-elective EVAR with the Bolton Treo endograft at 5 institutions located in the North-East of Italy (January 2016-December 2020) was performed. The main exposure variable for this study was presence of hostile (HAN) or friendly (FAN) aortic neck. RESULTS: A total of 137 consecutive patients were treated with the Bolton Treo endograft at participating institutions; of these 63 (46%) presented HAN while 74 (54%) had FAN. At baseline, no significant differences were observed in the distribution of demographics and comorbidities between study groups. Two type Ia endoleaks (EL) were detected at completion angiography, all in patients with HAN but none in patients with FAN (3% vs. 0%, P = 0.04), but no type III EL were identified in the whole cohort. The median duration of follow-up in the study cohort was 30 months (IQR 22-34 months) and was similar between study groups (P = 0.87). At 3-years, survival estimates were 89% and 91% (P= 0.82) in patients with HAN and FAN, respectively. At three years, patients with HAN had significantly lower freedom from type IA endoleak as compared with patients with FAN (87% vs. 94%, P= 0.02). No significant differences were found between study groups in the three-year estimates of freedom from reinterventions (80% vs. 86%, P= 0.28). Using cox proportional hazards, presence of type II EL (HR 3.15, 95%CI 1.18-8.5, P= 0.02) and presence of type IA EL (HR 4.22, 95%CI 1.39-12.85, P= 0.01) were found as independent predictors for reinterventions in univariate analysis, although they were no longer significant in the multivariate model. Freedom from sac increase >5mm at three years were not significantly different between study groups (92% vs 91%, P= 0.95). CONCLUSIONS: Within a contemporary multicentric real-world experience, EVAR with the Bolton Treo endograft shows a satisfactory safety profile in the immediate postoperative phase and acceptable outcomes during mid-term follow-up. Presence of HAN is correlated with development of type Ia EL (either early following stent-graft implantation or late after EVAR) which, in turn, may represent a significant factor leading to reinterventions.
引用
- D'Oria M, Galeazzi E, Veraldi GF, et al. Impact of Proximal Neck Anatomy on Short-Term and Mid-Term Outcomes After Treatment of Abdominal Aortic Aneurysms With New-Generation Low-Profile Endografts. Results From the Multicentric "ITAlian North-East Registry of ENDOvascular Aortic Repair With the BOltOn Treo Endograft (ITA-ENDOBOOT)". Ann Vasc Surg. 2021. PMID: 34752851. doi:10.1016/j.avsg.2021.08.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。